文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

司美替尼联合多西他赛对比多西他赛单药治疗KRAS突变晚期非小细胞肺癌的无进展生存期:SELECT-1随机临床试验

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项跨国随机临床试验纳入510例KRAS突变晚期非小细胞肺癌患者,比较司美替尼联合多西他赛与安慰剂联合多西他赛作为二线治疗的疗效。结果显示,联合组中位无进展生存期为3.9个月,对照组为2.8个月,差异无统计学意义(HR 0.93,95%CI 0.77-1.12,P=0.44);联合组3级及以上不良事件发生率为67%,高于对照组的45%。

要点

  • 司美替尼联合多西他赛未显著改善KRAS突变晚期NSCLC患者的无进展生存期(HR 0.93,P=0.44)。
  • 联合组中位总生存期8.7个月,对照组7.9个月,差异无统计学意义(HR 1.05,P=0.64)。
  • 联合组3级及以上不良事件发生率为67%,对照组为45%。

核心结论

  • 在既往接受过治疗的晚期KRAS突变非小细胞肺癌患者中,与多西他赛单药相比,联合司美替尼并未改善无进展生存期。

研究设计与样本

  • 跨国随机临床试验,于2013年10月至2016年1月在25个国家的202个中心开展。
  • 3323例晚期NSCLC且一线治疗后疾病进展的患者接受KRAS突变检测,866例入组,510例随机分组。
  • 患者按1:1随机分配至司美替尼联合多西他赛组(254例)或安慰剂联合多西他赛组(256例)。
  • 主要终点为研究者评估的无进展生存期;数据截止日期为2016年6月7日。

主要发现

  • 510例随机患者中,505例(99%)接受了治疗并完成研究(司美替尼联合多西他赛组251例,安慰剂联合多西他赛组254例)。
  • 截至数据截止时,447例(88%)发生进展事件,346例(68%)死亡。
  • 司美替尼联合多西他赛组中位无进展生存期为3.9个月(IQR 1.5-5.9),安慰剂联合多西他赛组为2.8个月(IQR 1.4-5.5),差异1.1个月,HR 0.93(95%CI 0.77-1.12),P=0.44。
  • 司美替尼联合多西他赛组中位总生存期为8.7个月(IQR 3.6-16.8),安慰剂联合多西他赛组为7.9个月(IQR 3.8-20.1),差异0.9个月,HR 1.05(95%CI 0.85-1.30),P=0.64。
  • 客观缓解率司美替尼联合多西他赛组为20.1%,安慰剂联合多西他赛组为13.7%,差异6.4%,比值比1.61(95%CI 1.00-2.62),P=0.05。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. OBJECTIVE: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC. DESIGN, SETTING, AND PARTICIPANTS: Multinational, randomized clinical trial conducted at 202 sites across 25 countries from October 2013 through January 2016. Of 3323 patients with advanced NSCLC and disease progression following first-line anticancer therapy tested for a KRAS mutation, 866 were enrolled and 510 randomized. Primary reason for exclusion was ineligibility. The data cutoff date for analysis was June 7, 2016. INTERVENTIONS: Patients were randomized 1:1; 254 to receive selumetinib + docetaxel and 256 to receive placebo + docetaxel. MAIN OUTCOMES AND MEASURES: Primary end point was investigator assessed progression-free survival. Secondary end points included overall survival, objective response rate, duration of response, effects on disease-related symptoms, safety, and tolerability. RESULTS: Of 510 randomized patients (mean age, 61.4 years [SD, 8.3]; women, 207 [41%]), 505 patients (99%) received treatment and completed the study (251 received selumetinib + docetaxel; 254 received placebo + docetaxel). At the time of data cutoff, 447 patients (88%) had experienced a progression event and 346 deaths (68%) had occurred. Median progression-free survival was 3.9 months (interquartile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.93 [95% CI, 0.77-1.12]; P = .44). Median overall survival was 8.7 months (IQR, 3.6-16.8) with selumetinib + docetaxel and 7.9 months (IQR, 3.8-20.1) with placebo + docetaxel (difference, 0.9 months; HR, 1.05 [95% CI, 0.85-1.30]; P = .64). Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel (difference, 6.4%; odds ratio, 1.61 [95% CI, 1.00-2.62]; P = .05). Median duration of response was 2.9 months (IQR, 1.7-4.8; 95% CI, 2.7-4.1) with selumetinib + docetaxel and 4.5 months (IQR, 2.3-7.3; 95% CI, 2.8-5.6) with placebo + docetaxel. Adverse events of grade 3 or higher were more frequent with selumetinib + docetaxel (169 adverse events [67%] for selumetinib + docetaxel vs 115 adverse events [45%] for placebo + docetaxel; difference, 22%). CONCLUSIONS AND RELEVANCE: Among patients with previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival compared with docetaxel alone. TRIAL REGISTRATION: clinicaltrials.gov: NCT01933932.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Jänne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA. 2017. PMID: 28492898. doi:10.1001/jama.2017.3438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。